After hours:
Chart Events
Performance Outlook
| Previous Close | 104.10 |
| Open | 104.82 |
| Bid | 105.39 x 2200 |
| Ask | 106.18 x 800 |
| Day's Range | 104.82 - 106.91 |
| 52 Week Range | 78.77 - 115.49 |
| Volume | |
| Avg. Volume | 8,646,194 |
| Market Cap | 268.372B |
| Beta (5Y Monthly) | 0.37 |
| PE Ratio (TTM) | 38.23 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.92 (2.76%) |
| Ex-Dividend Date | Mar 14, 2023 |
| 1y Target Est | N/A |
- Business Wire
Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
RAHWAY, N.J., March 16, 2023--Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A in Previously Treated Patients with mNSCLC
- Business Wire
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma
RAHWAY, N.J. & KINGSTON, Ontario, March 10, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group (CCTG) today announced that the Phase 2/3 CCTG IND.227/KEYNOTE-483 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met its primary endpoint of overall survival (OS) for the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. IND.227 was sponsored
- Business Wire
Merck to Present at the Barclays 2023 Global Healthcare Conference
RAHWAY, N.J., March 08, 2023--Merck to Present at the Barclays 2023 Global Healthcare Conference
